CS178129B2 - - Google Patents

Info

Publication number
CS178129B2
CS178129B2 CS3590A CS359073A CS178129B2 CS 178129 B2 CS178129 B2 CS 178129B2 CS 3590 A CS3590 A CS 3590A CS 359073 A CS359073 A CS 359073A CS 178129 B2 CS178129 B2 CS 178129B2
Authority
CS
Czechoslovakia
Application number
CS3590A
Other languages
Czech (cs)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20269234&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CS178129(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of CS178129B2 publication Critical patent/CS178129B2/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pain & Pain Management (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CS3590A 1972-05-19 1973-05-18 CS178129B2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE7206644A SE378109B (fr) 1972-05-19 1972-05-19

Publications (1)

Publication Number Publication Date
CS178129B2 true CS178129B2 (fr) 1977-08-31

Family

ID=20269234

Family Applications (1)

Application Number Title Priority Date Filing Date
CS3590A CS178129B2 (fr) 1972-05-19 1973-05-18

Country Status (26)

Country Link
US (2) US3929768A (fr)
JP (1) JPS5521760B2 (fr)
AT (1) AT328630B (fr)
BE (1) BE799727A (fr)
CA (1) CA1002938A (fr)
CH (1) CH595400A5 (fr)
CS (1) CS178129B2 (fr)
CY (1) CY1013A (fr)
DD (1) DD104295A5 (fr)
DE (1) DE2323215C3 (fr)
DK (1) DK134783B (fr)
ES (1) ES414673A1 (fr)
FI (1) FI50631C (fr)
FR (1) FR2185405B1 (fr)
GB (1) GB1429922A (fr)
HK (1) HK49179A (fr)
HU (1) HU166680B (fr)
IL (1) IL42155A (fr)
KE (1) KE2970A (fr)
NL (2) NL177493C (fr)
NO (2) NO139640C (fr)
PL (1) PL87765B1 (fr)
SE (1) SE378109B (fr)
SU (1) SU470954A3 (fr)
YU (1) YU35896B (fr)
ZA (1) ZA732955B (fr)

Families Citing this family (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8004580L (sv) * 1980-06-19 1981-12-20 Draco Ab Farmaceutisk beredning
SE8008524L (sv) * 1980-12-04 1982-06-05 Draco Ab 4-pregnen-derivat, ett forfarande for deras framstellning, beredning och metod for behandling av inflammatoriska tillstand
IT1196142B (it) * 1984-06-11 1988-11-10 Sicor Spa Procedimento per la preparazione di 16,17-acetali di derivati pregnanici e nuovi composti ottenuti
SE8403905D0 (sv) * 1984-07-30 1984-07-30 Draco Ab Liposomes and steroid esters
SE8501693D0 (sv) * 1985-04-04 1985-04-04 Draco Ab Novel 16,17-acetalsubstituted androstane-17beta-carboxylic acid esters
SE8506015D0 (sv) * 1985-12-19 1985-12-19 Draco Ab Novel 16,17-acetalsubstituted pregnane 21-oic acid derivatives
US5215979A (en) * 1985-12-19 1993-06-01 Aktiebolaget Draco 16,17-acetalsubstituted pregnane 21-oic acid derivatives
SE8604059D0 (sv) * 1986-09-25 1986-09-25 Astra Pharma Prod A method of controlling the epimeric distribution in the preparation of 16,17-acetals of pregnane derivatives
LV5274A3 (lv) * 1988-02-29 1993-10-10 Richter Gedeon Vegyeszet 22(R,S)-11 beta,21-dihidroksi-16 alpha,17-butilidenbisoksipregna-1,4-dien-3,20-diona iegusanas panemiens
HU203769B (en) * 1989-03-09 1991-09-30 Richter Gedeon Vegyeszet Process for producing new steroide derivatives and pharmaceutical compositions containing them
SE8903219D0 (sv) * 1989-10-02 1989-10-02 Astra Ab Process for the manufacture of budesonide
SE8903914D0 (sv) 1989-11-22 1989-11-22 Draco Ab Oral composition for the treatment of inflammatory bowel diseases
US5643602A (en) * 1989-11-22 1997-07-01 Astra Aktiebolag Oral composition for the treatment of inflammatory bowel disease
GR1001529B (el) * 1990-09-07 1994-03-31 Elmuquimica Farm Sl Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
SE9100342D0 (sv) * 1991-02-04 1991-02-04 Astra Ab Novel steroid esters
SE9100341D0 (sv) * 1991-02-04 1991-02-04 Astra Ab Novel steroids
US5888995A (en) * 1991-02-04 1999-03-30 Astra Aktiebolag Steroid esters
IE67345B1 (en) * 1991-03-12 1996-03-20 Akzo Nv Low dose dry pharmaceutical preparations
FR2675146A1 (fr) * 1991-04-10 1992-10-16 Roussel Uclaf Nouveaux derives sterouides de la pregna-1,4-diene-3,20-dione, leur preparation, leur application a la preparation de derives 16,17-methylene dioxy substitues et nouveaux intermediaires.
MD24C2 (ro) * 1991-07-09 1994-05-31 Fabrica De Parfumerii Si Cosmetica "Viorica" Compoziţie de substanţe odorante
LT3695B (en) 1991-11-18 1996-02-26 Dineika Raimundas Arnas Folded roof
HU0004452D0 (fr) * 1991-12-18 2001-01-29 Astra Ab
FI953130A0 (fi) * 1992-12-24 1995-06-22 Rhone Poulenc Rorer Ltd Uudet steroidit
ES2137353T3 (es) * 1993-01-08 1999-12-16 Astra Ab Nuevos derivados esteroides especificos del colon o del ileon.
CZ287877B6 (cs) 1993-04-02 2001-03-14 Byk Gulden Lomberg Chemische Fabrik Gmbh Prednisolonové deriváty a farmaceutické prostředky s jejich obsahem
GB9423919D0 (en) * 1994-11-26 1995-01-11 Rhone Poulenc Rorer Ltd Chemical process
US6166024A (en) 1995-03-30 2000-12-26 Mayo Foundation For Medical Education And Research Use of topical azathioprine and thioguanine to treat colorectal adenomas
FR2756739B1 (fr) * 1996-12-05 2000-04-28 Astra Ab Nouvelle formulation de budesonide
IT1291288B1 (it) 1997-04-30 1999-01-07 Farmabios Srl Processo per la preparazione di 16,17 acetali di derivati pregnanici con controllo della distribuzione epimerica al c-22.
DE29717252U1 (de) * 1997-09-26 1998-02-19 Dr. Falk Pharma GmbH, 79108 Freiburg Arzneimittelkit aus einem Budesonid-haltigen und einem Ursodesoxycholsäure-haltigen Arzneimittel zur Behandlung von cholestatischen Lebererkrankungen
US6266556B1 (en) 1998-04-27 2001-07-24 Beth Israel Deaconess Medical Center, Inc. Method and apparatus for recording an electroencephalogram during transcranial magnetic stimulation
US6667299B1 (en) * 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
AU777770C (en) 1999-05-04 2005-11-10 Strakan International Limited Androgen glycosides and androgenic activity thereof
GB0009584D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
GB0009583D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
GB0009613D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
AR028948A1 (es) 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
IL144900A (en) 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
US20040235811A1 (en) * 2002-10-08 2004-11-25 Sepracor Inc. Fatty acid modified forms of glucocorticoids
JP2006523674A (ja) * 2003-04-18 2006-10-19 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 慢性閉塞性肺疾患（ｃｏｐｄ）のための組合せ治療法
TWI359675B (en) * 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
JP2007504123A (ja) * 2003-08-29 2007-03-01 ランバクシー ラボラトリーズ リミテッド Ｉｖ型ホスホジエステラーゼの阻害剤
WO2005051931A2 (fr) * 2003-11-26 2005-06-09 Ranbaxy Laboratories Limited Inhibiteurs de la phosphodiestérase
CN1942470A (zh) 2004-04-09 2007-04-04 默克公司 Akt活性抑制剂
US8362075B2 (en) 2005-05-17 2013-01-29 Merck Sharp & Dohme Corp. Cyclohexyl sulphones for treatment of cancer
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
TW200738634A (en) 2005-08-02 2007-10-16 Astrazeneca Ab New salt
TW200744612A (en) * 2005-08-26 2007-12-16 Astrazeneca Ab New combination
WO2007031838A1 (fr) 2005-09-16 2007-03-22 Ranbaxy Laboratories Limited Pyrazolo[3,4-b]pyridines substituees en tant qu'inhibiteurs de la phosphodiesterase
AU2006305619A1 (en) 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Pharmaceutical compositions of muscarinic receptor antagonists
CA2626628A1 (fr) * 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Compositions d'inhibiteurs de la phosphodiesterase de type iv
JP2009512733A (ja) * 2005-11-02 2009-03-26 シコール インコーポレイティド シクレソニドの改良された製造法
TWI374147B (en) 2006-01-27 2012-10-11 Sun Pharma Advance Res Company Ltd Novel 11β-hydroxyandrosta-4-ene-3-ones
US20070232578A1 (en) * 2006-02-15 2007-10-04 Pierluigi Rossetto Crystalline forms of ciclesonide
ES2296516B1 (es) * 2006-04-27 2009-04-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
PT2074093E (pt) 2006-08-22 2013-01-24 Ranbaxy Lab Ltd Processo para a preparação de inibidores de metaloproteinases de matriz e seus auxiliares quirais
EP2066661A2 (fr) * 2006-09-22 2009-06-10 Ranbaxy Laboratories Limited Inhibiteurs de phosphodiesterase
MX2009003100A (es) * 2006-09-22 2009-05-11 Ranbaxy Lab Ltd Inhibidores de fosfodiesterasa tipo iv.
ES2302447B1 (es) * 2006-10-20 2009-06-12 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
DK2099442T3 (en) 2006-12-26 2015-02-16 Pharmacyclics Inc Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy
AU2008204380B2 (en) 2007-01-10 2013-08-15 Msd Italia S.R.L. Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
GB0702456D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination
ES2306595B1 (es) * 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
US10201490B2 (en) 2007-02-14 2019-02-12 Polichem Sa Use of chitosans for the treatment of nail inflammatory diseases
EP1958639A1 (fr) 2007-02-14 2008-08-20 Polichem S.A. Utilisation de chitosanes dans le traitement de maladies inflammatoires des ongles
EP1958947A1 (fr) 2007-02-15 2008-08-20 Ranbaxy Laboratories Limited Inhibiteurs de la phosphodiestérase de type 4
US20110130403A1 (en) * 2007-03-14 2011-06-02 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b] pyridine derivatives as phosphodiesterase inhibitors
HRP20120361T1 (hr) * 2007-03-14 2012-05-31 Ranbaxy Laboratories Limited DERIVATI PIRAZOLO[3,4-b]PIRIDINA KAO INHIBITORI FOSFODIESTERAZE
AU2008269154B2 (en) 2007-06-27 2014-06-12 Merck Sharp & Dohme Llc 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US20090082319A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched budesonide
US8796248B2 (en) * 2007-10-05 2014-08-05 Nektar Therapeutics Oligomer-corticosteroid conjugates
ES2320961B1 (es) * 2007-11-28 2010-03-17 Laboratorios Almirall, S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor adrenergico beta2.
EP2096105A1 (fr) * 2008-02-28 2009-09-02 Laboratorios Almirall, S.A. Dérivés de 4-(2-amino-1-hydroxyethyl)phénol en tant qu'antagonistes du récepteur adrénergique b2
PT2262823E (pt) * 2008-03-13 2013-03-05 Farmabios Spa Processo para a preparação de derivados de pregnano
ITMI20080645A1 (it) 2008-04-11 2009-10-12 Ind Chimica Srl Procedimento per la preparazione di budesonide
EP2111861A1 (fr) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions d'inhibiteurs de type IV de la phosphodiestérase
CN101279997B (zh) * 2008-05-29 2011-08-24 鲁南制药集团股份有限公司 布地奈德的一种制备方法
UY32297A (es) 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
GB0900484D0 (en) 2009-01-13 2009-02-11 Angeletti P Ist Richerche Bio Therapeutic agent
EP2228368A1 (fr) 2009-03-12 2010-09-15 Almirall, S.A. Procédé de fabrication de 5-(2-{[6-(2,2-difluoro-2-ph2nyl2thoxy)hexyl]amino}-1-hydroxy2thyl)-8-hydroxyquinolin-2(1h)-one
WO2010114780A1 (fr) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibiteurs de l'activité akt
US8603521B2 (en) 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
BRPI1011220B1 (pt) 2009-05-29 2020-03-10 Pearl Therapeutics, Inc. Composição farmacêutica administrável a partir de um inalador de dose medida compreendendo um meio de suspensão compreendendo um propelente, duas ou mais espécies diferentes de partículas de agente ativo e uma ou mais espécies de partículas respiráveis em suspensão
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
GB0916608D0 (en) 2009-09-22 2009-11-04 Angeletti P Ist Richerche Bio Therapeutic compounds
CA3037273C (fr) 2009-10-01 2022-05-03 Fredric Jay Cohen Compositions de corticosteroides administrees par voie orale
CN104945382B (zh) 2009-10-14 2020-02-07 默沙东公司 提高p53活性的取代的哌啶和其用途
WO2011073662A1 (fr) 2009-12-17 2011-06-23 Astrazeneca Ab Association d'une benzoxazinone et d'un autre agent pour le traitement de maladies respiratoires
WO2011093812A2 (fr) 2010-01-28 2011-08-04 Mahmut Bilgic Formulation pharmaceutique comprenant du tiotropium et du budésonide sous forme de poudre sèche
WO2011097594A2 (fr) 2010-02-08 2011-08-11 Kinagen, Inc. Methodes therapeutiques et compositions impliquant l'inhibition de la kinase allosterique
CN101863952B (zh) * 2010-04-30 2013-04-17 湖北葛店人福药业有限责任公司 布地奈德的制备方法
WO2011163330A1 (fr) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Nouveaux composés hétérocycliques utilisés comme inhibiteurs de erk
AU2011285909B2 (en) 2010-08-02 2016-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
EP3587574B1 (fr) 2010-08-17 2022-03-16 Sirna Therapeutics, Inc. Inhibition médiée par des arn interférents de l'expression génique du virus de l'hépatite b (vhb) à l'aide de petits acides nucléiques interférents (pani)
EP2608669B1 (fr) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. Nouveaux dérivés de pyrazolo[1,5-a]pyrimidine utilisés comme inhibiteurs de mtor
WO2012030685A2 (fr) 2010-09-01 2012-03-08 Schering Corporation Dérivés d'indazole utilisables en tant qu'inhibiteurs de la voie erk
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
DK2632472T3 (en) 2010-10-29 2018-03-19 Sirna Therapeutics Inc RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
EP2654748B1 (fr) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Dérivés d'indazole utiles en tant qu'inhibiteurs de erk
EP2699568A1 (fr) 2011-04-21 2014-02-26 Piramal Enterprises Limited Forme cristalline d'un sel d'un dérivé de morpholinosulfonylindole et son procédé de préparation
NZ621221A (en) 2011-09-13 2016-07-29 Pharmacyclics Llc Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
EP2578570A1 (fr) 2011-10-07 2013-04-10 Almirall, S.A. Nouveau procédé de fabrication de 5-(2-{[6-(2,2-difluoro-2-phényléthoxy)hexyl]amino}-1-hydroxyéthyl)-8-hydroxyquinolin-2(1h)-one via de nouveaux intermédiaires de synthèse
EP2770987B1 (fr) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Nouveaux composés qui sont des inhibiteurs d'erk
WO2013109214A1 (fr) 2012-01-16 2013-07-25 Mahmut Bilgic Procédé de préparation de formulations en poudre sèche
EP2641900A1 (fr) 2012-03-20 2013-09-25 Almirall, S.A. Nouvelles formes polymorphes de héminapadisylate de 5-(2-{[6-(2,2-difluoro-2-phényléthoxy) hexyl]amino}-1-(R)-hydroxyéthyl)-8-hydroxyquinolin-2(1h)-one en tant qu'agoniste du récepteur adrénergique ß2
EP3453762B1 (fr) 2012-05-02 2021-04-21 Sirna Therapeutics, Inc. Compositions d'acide nucléique interférent court (sina)
CN103421075B (zh) * 2012-05-16 2017-07-28 上海特化医药科技有限公司 孕烷衍生物16,17‑缩醛(酮)的制备方法
WO2014007781A2 (fr) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Compositions d'inhalation
WO2014007772A2 (fr) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Compositions d'inhalation contenant du glucose anhydre
WO2014007770A2 (fr) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Compositions d'inhalation comprenant un corticostéroïde et du sorbitol
US10105316B2 (en) 2012-07-05 2018-10-23 Arven llac Sanayi Ve Ticaret A.S. Inhalation compositions comprising muscarinic receptor antagonist
EP2888255B1 (fr) 2012-08-24 2018-07-18 Board of Regents, The University of Texas System Modulateurs hétérocycliques de l'activité du facteur hif utilisés pour le traitement de maladies
KR20150060724A (ko) 2012-09-28 2015-06-03 머크 샤프 앤드 돔 코포레이션 Erk 억제제인 신규 화합물
RS56680B1 (sr) 2012-11-28 2018-03-30 Merck Sharp & Dohme Kompozicije i postupci za lečenje kancera
MX373639B (es) 2012-12-20 2020-05-04 Merck Sharp & Dohme Imidazopiridinas sustituidas como inhibidores de doble minuto 2 humana.
EP2951180B1 (fr) 2013-01-30 2018-05-02 Merck Sharp & Dohme Corp. Purines 2,6,7,8-substituées utilisées en tant qu'inhibiteurs de hdm2
TR201902687T4 (tr) 2013-03-15 2019-03-21 Pearl Therapeutics Inc İri parçacıklı kristal malzemelerin koşullandırılması için yöntemler ve sistemler.
WO2014190204A1 (fr) 2013-05-22 2014-11-27 Pearl Therapeutics, Inc. Compositions, procedes & systemes pour l'administration par voie respiratoire d'au moins trois agents actifs
WO2015034925A1 (fr) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Polynucléotides circulaires
WO2015034678A2 (fr) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticostéroïde contenant des compositions de comprimés se désintégrant par voie orale pour œsophagite à éonisophiles
CA2936746C (fr) 2014-10-31 2017-06-27 Purdue Pharma Methodes et compositions destinees au traitement du trouble de deficit d'attention
US10233210B2 (en) 2015-01-30 2019-03-19 Coral Drugs Pvt. Ltd. Process for preparation of glucocorticoid steroids
EP3475275B1 (fr) 2016-06-23 2024-04-10 Merck Sharp & Dohme LLC 5-trifluorométhyl-oxadiazoles substitués en 3-aryle et hétéroaryle en tant qu'inhibiteurs de l'histone désacétylase 6 (hdac6)
TWI728172B (zh) 2016-08-18 2021-05-21 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
KR20190074310A (ko) 2016-11-08 2019-06-27 리제너론 파마슈티칼스 인코포레이티드 스테로이드 및 이의 단백질-접합체
IL270594B2 (en) 2017-05-18 2024-06-01 Regeneron Pharma Cyclodextrin protein drug conjugates
CN111601619A (zh) 2017-11-07 2020-08-28 里珍纳龙药品有限公司 用于抗体药物偶联物的亲水性连接体
WO2019094312A1 (fr) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
MA50259A1 (fr) 2018-01-08 2021-07-29 Regeneron Pharma Stéroïdes et leurs conjugués-anticorps
JP7590871B2 (ja) 2018-05-09 2024-11-27 レゲネロン ファーマシューティカルス，インコーポレーテッド 抗ｍｓｒ１抗体及びその使用方法
US11993602B2 (en) 2018-08-07 2024-05-28 Merck Sharp & Dohme Llc PRMT5 inhibitors
KR20210046009A (ko) 2018-08-07 2021-04-27 머크 샤프 앤드 돔 코포레이션 Prmt5 억제제
WO2020033284A1 (fr) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
EP4077282A4 (fr) 2019-12-17 2023-11-08 Merck Sharp & Dohme LLC Inhibiteurs de prmt5
EP4076459A4 (fr) 2019-12-17 2023-12-20 Merck Sharp & Dohme LLC Inhibiteurs de prmt5
US12441730B2 (en) 2019-12-17 2025-10-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
WO2023283441A1 (fr) 2021-07-09 2023-01-12 Astrazeneca Pharmaceuticals Lp Compositions, méthodes et systèmes pour l'administration d'un médicament en aérosol
US20250057764A1 (en) 2021-12-20 2025-02-20 Astrazeneca Ab Compositions, methods and systems for aerosol drug delivery
CA3265870A1 (fr) 2022-09-02 2024-03-07 Merck Sharp & Dohme Llc Compositions pharmaceutiques à base d'inhibiteurs de la topoisomérase-1 dérivés de l'exatécan, et leurs utilisations
KR20250079227A (ko) 2022-10-25 2025-06-04 머크 샤프 앤드 돔 엘엘씨 엑사테칸-유래 adc 링커-페이로드, 제약 조성물, 및 그의 용도
IL321395A (en) 2022-12-14 2025-08-01 Merck Sharp & Dohme Llc Auristatin cargo-linkers, pharmaceutical compounds, and their uses

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3126375A (en) * 1964-03-24 Chioacyl
US3133940A (en) * 1956-04-10 1964-05-19 Glaxo Group Ltd Process for the separation of delta-1, 4-3-keto steroid compounds from mixtures thereof with other 3-keto steroids
US2990401A (en) * 1958-06-18 1961-06-27 American Cyanamid Co 11-substituted 16alpha, 17alpha-substituted methylenedioxy steroids
US3197469A (en) * 1958-08-06 1965-07-27 Pharmaceutical Res Products In 16, 17-acetals and ketals of 6-halo-16, 17-dihydroxy steroids of the pregnane seriesand intermediates therefor
US3048581A (en) * 1960-04-25 1962-08-07 Olin Mathieson Acetals and ketals of 16, 17-dihydroxy steroids
US3128238A (en) * 1962-09-14 1964-04-07 Lilly Co Eli delta1-dehydrogenation of steroids by fermentation with actinoplanaceae
JPS4843910A (fr) * 1971-10-08 1973-06-25

Also Published As

Publication number Publication date
US3929768A (en) 1975-12-30
JPS5521760B2 (fr) 1980-06-12
BE799727A (fr) 1973-09-17
PL87765B1 (fr) 1976-07-31
YU129173A (en) 1981-02-28
NO139640B (no) 1979-01-08
HU166680B (fr) 1975-05-28
CA1002938A (en) 1977-01-04
SE378109B (fr) 1975-08-18
HK49179A (en) 1979-07-27
GB1429922A (en) 1976-03-31
SU470954A3 (ru) 1975-05-15
DE2323215A1 (de) 1973-11-29
DE2323215C3 (de) 1978-03-30
IL42155A (en) 1977-06-30
DE2323215B2 (de) 1977-08-11
FR2185405A1 (fr) 1974-01-04
FR2185405B1 (fr) 1976-12-31
FI50631B (fr) 1976-02-02
NL930025I1 (nl) 1993-06-01
IL42155A0 (en) 1973-07-30
DK134783C (fr) 1977-06-06
ATA436573A (de) 1975-06-15
NL7306978A (fr) 1973-11-21
NL177493B (nl) 1985-05-01
AT328630B (de) 1976-03-25
NO139640C (no) 1979-04-18
ES414673A1 (es) 1976-07-01
DD104295A5 (fr) 1974-03-05
YU35896B (en) 1981-08-31
CH595400A5 (fr) 1978-02-15
US3983233A (en) 1976-09-28
JPS4941378A (fr) 1974-04-18
DK134783B (da) 1977-01-17
NL177493C (nl) 1985-10-01
ZA732955B (en) 1974-04-24
AU5525373A (en) 1974-11-07
KE2970A (en) 1979-07-20
CY1013A (en) 1979-11-23
FI50631C (fi) 1976-05-10
NO1994013I1 (no) 1994-08-31

Similar Documents

Publication Publication Date Title
CS154515B1 (fr)
CS154517B1 (fr)
CS156799B1 (fr)
CH579579A5 (fr)
CH573012B5 (fr)
CH1372372A4 (fr)
CH1570473A4 (fr)
CH1573A4 (fr)
CH414172A4 (fr)
CH560463A5 (fr)
CH560498A5 (fr)
CH560843A5 (fr)
CH561030A5 (fr)
CH561041A5 (fr)
CH561588A5 (fr)
CH561888A5 (fr)
CH563955A5 (fr)
CH563970A5 (fr)
CH564084A5 (fr)
CH564490A5 (fr)
CH564806A5 (fr)
CH564894A5 (fr)
CH564939A5 (fr)
CH565273A (fr)
CH565333A5 (fr)